For The Asking, A Check Is In The Mail To Help Pay For Costly Drugs
It’s a little-known secret that patients can get thousands of dollars directly from a drugmaker.
Government Investigation Finds Flaws In the FDA’s Orphan Drug Program
A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.
Trump Adds A Global Pricing Plan To Wide Attack On Drug Prices, But Doubts Persist
Over the past five months, the Trump administration has proposed a series of reforms to lower the cost of prescription drugs.
TV Ads Must Trumpet Drug Prices, Trump Administration Says. Pharma Tries A Plan B.
Drug pricing is a top issue in the run-up to the midterm elections.
Drugmakers Play The Patent Game To Lock In Prices, Block Competitors
Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now there’s a twist involving an opioid treatment.
Déjà Voodoo: Pharma’s Promises To Curb Drug Prices Have Been Heard Before
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
Top Policy Expert’s Ties To Giant Drugmaker Often Go Unstated
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
Trump Vows (Again) To Lower Drug Prices But Skeptics Doubt Much Will Change
President Donald Trump’s much-awaited speech about slashing drug costs was long on rhetoric but short on specifics that will reduce prices.
For The Babies Of The Opioid Crisis, The Best Care May Be Mom’s Recovery
Research is just beginning on infants born with neonatal abstinence syndrome, and doctors are optimistic that normal development is possible. Monitoring the families and making sure parents are treated for addiction is key.
Dissecting The Rhetoric Vs. Reality Of Trump’s Tough Talk On Drug Prices
President Donald Trump’s upcoming speech on drug prices comes after months of public comments and debate about tackling the issue.